Most of 2024 Simon as CTO had a free hand and took the initiative to speed up development. Before we sell stuff, we have to produce stuff to sell and before that we have to have prototypes. What deals can we make with anyone without even prototypes yet?
Now we may have some prototypes (TMR sensors??) ready to go soon and to make quick decisions and talk to the right people we need a CEO. What hampered Mo was that for several years he had to talk theoretical what ifs and not run before we could walk properly. Now Simon has a much clearer path to product and from that commercialisation. He was primarily a productization specialist. Now he has to, oversee 2 if not 3 product developments at various stages. I somehow feel he has decided to go all in for 12CQ development for now. It could well be the one thing that gets us riding every quantum wave and helps us get SP up, interest up and generally keep us in contention.
We will still get some biochip technical progress updates but as everyone has now realised clinical trials are planned in the US and can take a while to get approval. Big buying will mainly be for quantum news. As I have pointed out often, most analysts and researchers have no clue how to value Quantum and so it can attract FOMO buying. The risk of not buying is too great. What if a seemingly random progress update proves to be something that Google say, is suddenly interested in. I was just reading today that Google's Willow used the work of university of Sydney people to help with the impressive error correction technique!! Australian quantum is definitely a unique and valuable commodity.
AXE Price at posting:
31.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)